118 Results for "

BD2

" in MedChemExpress (MCE) Product Catalog:
Products (118)

118 Results for "BD2" in MCE Product Catalog:

  • Categories Recommended:
    More
Cat. No.: HY-153241
CAS No.: 2748687-95-6
Purity:  99.89%
Research Areas:  

Cancer

GSK737 is a BRD4 BD1 and BD2 inhibitor, with pIC50 values of 5.3 and 7.3 respectively. GSK737 has low clearance and good solubility and permeability in rat .
loading...
    loading...
Cat. No.: HY-151533
CAS No.: 2819989-67-6
Research Areas:  

Cancer

PBRM1-BD2-IN-6 is a potent PBRM1 bromodomain inhibitor with an IC50 value of 0.22 μM. PBRM1-BD2-IN-6 shows antiproliferation activity. PBRM1-BD2-IN-6 has the potential for the research of PBRM1-dependent cancer .
loading...
    loading...
Cat. No.: HY-111977
CAS No.: 1952264-34-4
Purity:  99.75%
Research Areas:  

Cancer

ZEN-3219 is a BET inhibitor with IC50s of 0.48, 0.16 and 0.47 μM for BRD4(BD1), BRD4(BD2) and BRD4(BD1BD2), respectively. ZEN-3219 can be used to form PROTACs to induce degradation of BRD4 .
loading...
    loading...
Cat. No.: HY-111979
CAS No.: 1952264-36-6
Research Areas:  

Cancer

ZEN-3411 is a BET inhibitor with IC50s of 0.05, 0.05 and 0.06 μM for BRD4(BD1), BRD4(BD2) and BRD4(BD1BD2), respectively. ZEN-3411 can be used to form PROTACs to induce degradation of BRD4 .
loading...
    loading...
Cat. No.: HY-111978
CAS No.: 1952264-33-3
Purity:  98.86%
Research Areas:  

Cancer

ZEN-3862 is a BET inhibitor with IC50s of 0.16 and 0.13 μM for BRD4(BD1) and BRD4(BD2) , respectively. ZEN-3862 can be used to form PROTACs to induce degradation of BRD4 .
loading...
    loading...
Cat. No.: HY-170380
XY221 (Compound 16o) selectively inhibits BRD4 BD2, with an IC50 of 5.8 nM. XY221 demonstrates high pan-BD2 selectivity (667-fold over BRD4 BD1) and BRD4 BD2 domain selectivity (9−32-fold over BRD2/3/T BD2). XY221 induce Apoptosis in MV4-11 cells and shows anticancer activity .
loading...
    loading...
Cat. No.: HY-142675
CAS No.: 2743464-27-7
Research Areas:  

Cancer

BRD4-BD1/2-IN-2 is a potent BRD4 BD2 inhibitor with IC50s of <0.5 nM and <300 nM for BRD4 BD2 and BRD4 BD1, respectively (WO2021233371A1, compound 2) .
loading...
    loading...
Cat. No.: HY-132230
CAS No.: 2752331-09-0
Research Areas:  

Inflammation/Immunology Cancer

GSK040 is a potent and highly selective BET BD2 inhibitor, with a pIC50 of 8.3. GSK040 shows more than 5000-fold selectivity for BET BD2 over BET BD1 (pIC50=4.6). GSK040 can be used for the research of oncology and immunology diseases .
loading...
    loading...
Cat. No.: HY-155680
CAS No.: 2677039-24-4
Research Areas:  

Inflammation/Immunology

BET BD2-IN-1 (compound 45) is a potent and selective inhibitor of BET BD2 (IC50=1.6 nM). BET BD2-IN-1 inhibits the differentiation of Th17 cells by decreasing the activation of STAT3 and NF-κB. BET BD2-IN-1 is used in psoriasis and inflammatory bowel disease (IBD) research .
loading...
    loading...
Cat. No.: HY-159602
CAS No.: 2677039-66-4
Research Areas:  

Cancer

BET BD2-IN-3 (compound I-58) is an inhibitor of BET, targeting the BD2 domain of BET. BET BD2-IN-3 can be radiolabeled with [11C] for positron emission tomography (PET) imaging. BET [11C]BD2-IN-3 showed suitable biodistribution in peripheral organs and tissues in PET applications in mice .
loading...
    loading...
Cat. No.: HY-151530
CAS No.: 2819989-58-5
Research Areas:  

Cancer

PBRM1-BD2-IN-3 (compound 12) is a potent PBRM1-BD2 inhibitor with an IC50 value of 1.1 μM. PBRM1-BD2 Inhibitor can be used to research anticancer .
loading...
    loading...
Cat. No.: HY-151534
CAS No.: 2819989-68-7
Research Areas:  

Cancer

PBRM1-BD2-IN-7 is a selective and cell-active polybromo-1 (PBRM1) bromodomain inhibitor. PBRM1-BD2-IN-7 has inhibitory activity for PBRM1-BD2 with an IC50 value of 0.29 μM. PBRM1-BD2-IN-7 can be used for the research of cancer .
loading...
    loading...
Cat. No.: HY-147573
CAS No.: 2760307-53-5
Research Areas:  

Cancer

BRD4 Inhibitor-23 is a potent and orally active BRD4 inhibitor with IC50s of 6.21 nM and 1.44 nM for BRD4 BD-1 and BRD4 BD-2, respectively (WO2022033542A1; Example 1) .
loading...
    loading...
Cat. No.: HY-129201
CAS No.: 1616400-50-0
Purity:  99.51%
Research Areas:  

Cancer

ZEN-2759 is a non-covalent BRD4 inhibitor with IC50 values of 0.23, 0.08, and 0.28 μM for BRD4 (BD1), BRD4 (BD2), and BRD4 (BD1BD2), respectively. ZEN-2759 can be used for cancer research [2].
loading...
    loading...
Cat. No.: HY-16652R
CAS No.: 1044870-39-4
Synonyms: RVX-208 (Standard); RVX000222 (Standard)
Research Areas:  

Cancer

Apabetalone (Standard) is the analytical standard of Apabetalone. This product is intended for research and analytical applications. Apabetalone (RVX-208) is an inhibitor of BET transcriptional regulators with selectivity for the second bromodomain. The IC50s are 87 μM and 0.51 μM for BD1 and BD2, respectively .
loading...
    loading...
Cat. No.: HY-143300
CAS No.: 2761321-26-8
Research Areas:  

Cardiovascular Disease Cancer

BRD4-BD1-IN-2 is a selective BRD4-BD1 inhibitor, with an IC50 of 2.51 µM (20-times greater than that of BD2). BRD4-BD1-IN-2 can be used in studies of cancer and cardiovascular diseases .
loading...
    loading...
Cat. No.: HY-151894
CAS No.: 3035187-74-4
Research Areas:  

Cancer

I-BET432 is a BET inhibitor. I-BET432 inhibits BRD4 N-terminal bromodomain (BD1) and the C-terminal bromodomain (BD2) with pIC50 values of 7.5 and 7.2, respectively. I-BET432 can be used as an oral candidate quality molecule for the research of multiple oncology and inflammatory diseases .
loading...
    loading...
Cat. No.: HY-175354
Target:  

PROTACs E1/E2/E3 Enzyme

Research Areas:  

Others

PROTAC BET Degrader-13 is a BET PROTAC degrader that recruits TRIM21. PROTAC BET Degrader-13 utilizes wild-type TRIM21 to mediate the degradation of PML-eGFP-BRD4 (BD2) fusion protein aggregates, with an EC50 of 1.4 μM in A549 cells expressing TRIM21-FLAG. PROTAC BET Degrader-13 can be used for research on targeted protein degradation and protein aggregate clearance .
loading...
    loading...
Cat. No.: HY-178510
Research Areas:  

Cancer

JQ1-S (GlcNAc) Cq is a sugar-modified BRD4 PROTAC degrader with a DC50 of 2.1 μM. JQ1-S (GlcNAc) Cq inhibits the formation of the ternary complex between CRBN and BRD4 (BD1/BD2). JQ1-S (GlcNAc) Cq serves as a substrate for O-GlcNAcase, which cleaves its O-GlcNAc domain to restore binding ability with CRBN, thereby forming a BRD4-containing ternary complex and triggering ubiquitination and proteasomal degradation of BRD4. JQ1-S (GlcNAc) Cq is applicable for cancer research .
loading...
    loading...
Cat. No.: HY-143317
CAS No.: 2933176-32-8
Research Areas:  

Cancer

XY153 (compound 8l) is a BD2-selective BET inhibitor and selectively binds to BRD4 BD2. XY153 binds to BRD4 BD2, BRD3 BD2 and BRD2 BD2 with IC50s of 0.79, 5.31 and 5.09 nM, respectively. XY153 shows potent antiproliferative activity against multiple tumor cell lines. XY153 can be used for the research of acute myeloid leukemia (AML) and cancer .
loading...
    loading...